MTAP and pancreatic ductal adenocarcinoma: To further evaluate the potential of exploiting the synthetic lethality introduced by MTAP deficiency in ductal adenocarcinoma of the pancreas we expanded our initial cohort for a better assessment of clinicopathological relationships and evaluated the intratumoral heterogeneity of MTAP deficiency in cancers from more than 200 patients.